J. Kellogg Parsons, MD, MHS, presented “Prostate Cancer Screening & Genetic Testing: The NCCN Perspective” for the Grand Rounds in Urology audience in January, 2020.
How to cite: Parsons, J. Kellogg. “Prostate Cancer Screening & Genetic Testing: The NCCN Perspective” January, 2020. Accessed Aug 2022. https://dev.grandroundsinurology.com/prostate-cancer-screening-genetic-testing-the-nccn-perspective/
Prostate Cancer Screening & Genetic Testing: The NCCN Perspective – Summary:
J. Kellogg Parsons, MD, MHS, discusses the rationale behind the National Comprehensive Cancer Network (NCCN) guidelines on prostate cancer screening and how they fit in with currently available genetic testing. He describes the multi-disciplinary makeup of the NCCN, details considerations that led to their recommendations on when men should be screened and in which circumstances, and outlines opportunities to improve the guidelines through standardization, coordination with other organizations, and improved treatment algorithms.
This educational activity is based on a series of lectures on genetic testing for prostate cancer from the 2019 Philadelphia Prostate Cancer Consensus Conference. Further activities from this conference include:
Germline Predisposition for Prostate Cancer Among African American and Other Minorities: What Do We Know?
Molecular Insights into the Germline for Prostate Cancer Initiation, Progression, and Aggressiveness
A Urologist’s Perspective on Germline Testing
Integration of Germline Testing in Prostate Cancer Screening
Current NCCN Recommendations for Prostate Cancer Genetic Testing
The Expanding World of Germline Testing for Prostate Cancer: Genetic Counseling Perspective
The Expanding World of Germline Testing for Prostate Cancer: A Clinical Trials Perspective
Current Prostate Cancer Genetic Testing Capabilities and Considerations